David A. Siegel Syndax Pharmaceuticals Inc Transaction History

Two Sigma Advisers, LP

$47 Billion
Q3 2025

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Syndax Pharmaceuticals Inc stock. As of the latest transaction made, Two Sigma Advisers, LP holds 383,052 shares of SNDX stock, worth $6.37 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

383,052

Previous 392,452 2.4%

Holding current value

$6.37 Million

Previous $3.68 Million 60.32%

% of portfolio

0.01%

Previous 0.01%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	SELL	$8.73 - $17.04 $82,062 - $160,176	-9,400 Reduced 2.4%	383,052 $5.9 Million
Q2 2025 Aug 14, 2025	SELL	$8.9 - $14.15 $985,230 - $1.57 Million	-110,700 Reduced 22.0%	392,452 $3.68 Million
Q1 2025 May 15, 2025	SELL	$12.29 - $16.38 $403,112 - $537,264	-32,800 Reduced 6.12%	503,152 $6.18 Million
Q4 2024 Feb 14, 2025	SELL	$12.52 - $21.81 $1.67 Million - $2.91 Million	-133,400 Reduced 19.93%	535,952 $7.09 Million
Q3 2024 Nov 14, 2024	BUY	$17.93 - $24.81 $862,433 - $1.19 Million	48,100 Added 7.74%	669,352 $12.9 Million

Q2 2024 Aug 14, 2024	BUY	$18.82 - $23.79 $3.11 Million - $3.93 Million	165,400 Added 36.28%	621,252 $12.8 Million
Q1 2024 May 15, 2024	BUY	$19.71 - $24.57 $6 Million - $7.48 Million	304,400 Added 200.99%	455,852 $10.8 Million
Q4 2023 Feb 14, 2024	BUY	$11.39 - $21.67 $961,316 - $1.83 Million	84,400 Added 125.87%	151,452 $3.27 Million
Q3 2023 Nov 14, 2023	SELL	$14.52 - $21.77 $1.02 Million - $1.53 Million	-70,100 Reduced 51.11%	67,052 $973,000
Q2 2023 Aug 14, 2023	SELL	$19.35 - $22.31 $2.44 Million - $2.82 Million	-126,200 Reduced 47.92%	137,152 $2.87 Million
Q1 2023 May 15, 2023	SELL	$20.66 - $28.98 $1.13 Million - $1.58 Million	-54,500 Reduced 17.15%	263,352 $5.56 Million
Q4 2022 Feb 14, 2023	SELL	$20.64 - $26.24 $1.11 Million - $1.41 Million	-53,900 Reduced 14.5%	317,852 $8.09 Million
Q3 2022 Nov 14, 2022	BUY	$18.51 - $24.79 $349,839 - $468,531	18,900 Added 5.36%	371,752 $8.93 Million
Q2 2022 Aug 15, 2022	SELL	$13.64 - $19.48 $211,420 - $301,940	-15,500 Reduced 4.21%	352,852 $6.79 Million
Q1 2022 May 16, 2022	BUY	$14.84 - $22.15 $204,792 - $305,670	13,800 Added 3.89%	368,352 $6.4 Million
Q4 2021 Feb 14, 2022	BUY	$15.23 - $22.47 $193,421 - $285,369	12,700 Added 3.72%	354,552 $7.76 Million
Q3 2021 Nov 15, 2021	SELL	$13.87 - $19.8 $1.2 Million - $1.71 Million	-86,600 Reduced 20.21%	341,852 $6.53 Million
Q2 2021 Aug 16, 2021	SELL	$13.42 - $25.18 $2.06 Million - $3.86 Million	-153,300 Reduced 26.35%	428,452 $7.36 Million
Q1 2021 May 17, 2021	SELL	$19.28 - $24.59 $1.65 Million - $2.11 Million	-85,800 Reduced 12.85%	581,752 $13 Million
Q4 2020 Feb 16, 2021	BUY	$15.1 - $26.44 $6.17 Million - $10.8 Million	408,500 Added 157.69%	667,552 $14.8 Million
Q3 2020 Nov 16, 2020	BUY	$13.39 - $17.48 $783,315 - $1.02 Million	58,500 Added 29.17%	259,052 $3.82 Million
Q2 2020 Aug 14, 2020	BUY	$8.94 - $20.98 $1.33 Million - $3.13 Million	149,000 Added 289.03%	200,552 $2.97 Million
Q1 2020 May 15, 2020	BUY	$6.65 - $12.03 $113,715 - $205,713	17,100 Added 49.63%	51,552 $566,000
Q4 2019 Feb 14, 2020	BUY	$5.43 - $9.22 $187,074 - $317,647	34,452 New	34,452 $302,000

Others Institutions Holding SNDX

# of Institutions

253

Shares Held

99.8M

Call Options Held

1.41M

Put Options Held

737K

View Full List

About Syndax Pharmaceuticals Inc

Ticker SNDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,565,200
Market Cap $940M
Description
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...

More about SNDX

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account